华兰生物工程股份有限公司 2025 年年度报告全文 华兰生物工程股份有限公司 2025 年年度报告 2026 年 3 月 28 日 1 华兰生物工程股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人安康、主管会计工作负责人李萍及会计机构负责人（会计主 管人员）丁珍声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本报告中详细描述可能存在的相关风险，敬请查阅本报告第三 节"管理层讨论与分析"第十一项"公司未来发展的展望"中"可能对公司 未来发展战略和经营目标的实现产生不利影响的风险因素"。 公司经本次董事会审议通过的利润分配预案为：以 1,827,456,666 为基 数，向全体股东每 10 股派发现金红利 5 元（含税），送红股 0 股（含税）， 不以公积金转增股本。 2 | | | | 第二节 | 公司简介和主要财务指标 6 | | --- | --- | | 第三节 ...

成都银河磁体股份有限公司 2025 年年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证本年度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 股票代码：300127 股票简称：银河磁体 披露日期：2026 年 3 月 28 日 成都银河磁体股份有限公司 Chengdu Galaxy Magnets Co.,Ltd. 2025 年年度报告 公司负责人戴炎、主管会计工作负责人朱魁文及会计机构负责人(会计主管人员)任晓莉 声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司对任何投资者 及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 | 第一节 | 重要提示、目录和释义 | | 1 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | | 5 | | 第三节 | 管理层讨论与分析 | | 8 | | 第四节 | 公司治理、环境和 ...

潮州三环（集团）股份有限公司 2025 年年度报告全文 潮州三环（集团）股份有限公司 2025 年年度报告 【披露时间】 1 潮州三环（集团）股份有限公司 2025 年年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人马艳红、主管会计工作负责人王洪玉及会计机构负责人(会计 主管人员)王洪玉声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，敬请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"之"十一、公司未来发展的 展望"部分，详细描述了公司经营中可能存在的风险，敬请投资者关注相关 内容。 公司经本次董事会审议通过的利润分配预案为：以 2025 年 12 月 31 日总 股本 1,916,497,371 股剔除回购专用账户中已回购股份 5,133,800 股后的股 本 1,911,363,571 股为基数，向全体股东每 10 股派发现 ...

株洲中车时代电气股份有限公司 2025 年年度报告 公司代码：688187 公司简称：时代电气 株洲中车时代电气股份有限公司 2025 年年度报告 1 / 319 株洲中车时代电气股份有限公司 2025 年年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 □是 √否 三、 重大风险提示 请查阅本报告第四节"管理层讨论与分析"中有关风险的说明。 四、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 徐绍龙 | 因重要公务 | 李东林 | 五、 毕马威华振会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人李东林、主管会计工作负责人孙珊及会计机构负责人（会计主管人员）袁峰声明： 保证年度报告中财务报告的真实、准确、完整。 公司拟以实施权益分派股权登记日（具体日期将在权益分派实施公告中明确）登记的总股本为基 ...

公司代码：605183 公司简称：确成股份 确成硅化学股份有限公司 2025 年年度报告 确成硅化学股份有限公司2025 年年度报告 1 / 235 确成硅化学股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人阙伟东、主管会计工作负责人王今及会计机构负责人（会计主管人员）曹力荣 声明：保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司拟以实施权益分派股权登记日登记的总股本扣除回购账户以及已回购未注销的限制性股票后 的股本为基数，向全体股东每 10 股派发现金红利人民币 4.00 元（含税）。如果在实施权益分派 的股权登记日前，因回购股份、股权激励授予股份回购注销等致使公司总股本发生变动的，公司 拟维持每股分配比例不变，相应调整分配总额。具体内容请见公司同日在上海证券交易所网站 （www. ...

Financial Performance - The company's operating revenue for 2025 was ¥2,418,234,933.46, a decrease of 14.29% compared to ¥2,821,441,302.71 in 2024[20]. - The net profit attributable to shareholders for 2025 was ¥177,741,534.70, an increase of 25.03% from ¥142,160,410.01 in 2024[20]. - The net cash flow from operating activities decreased by 52.64% to ¥490,926,166.16 in 2025 from ¥1,036,524,527.50 in 2024[20]. - The total assets at the end of 2025 were ¥12,070,589,241.26, down 18.02% from ¥14,724,311,909.25 at the end of 2024[20]. - The basic earnings per share for 2025 was ¥0.1111, reflecting a 24.97% increase from ¥0.0889 in 2024[20]. - The weighted average return on equity for 2025 was 1.91%, an increase of 0.40% from 1.51% in 2024[20]. - The company reported a total of ¥82,290,674.42 in non-recurring gains for 2025, compared to ¥33,764,335.24 in 2024[26]. - Revenue from self-developed vaccines accounted for 89% of total revenue in 2025, totaling ¥2,152,143,841.01, down 15.34% from ¥2,542,114,326.59 in 2024[76]. - The gross margin for the biopharmaceutical sector was 74.56%, a decrease of 5.13% year-over-year[77]. - Sales volume of vaccines decreased by 12.80% to 20,852,385 doses in 2025, while production volume fell by 14.15% to 19,916,911 doses[79]. Dividend and Profit Distribution - The company reported a cash dividend of 1.25 CNY per 10 shares (including tax) for the 2025 fiscal year, with no bonus shares issued[4]. - The company approved a cash dividend of RMB 0.10 per 10 shares for the 2024 fiscal year, with a total cash dividend amounting to RMB 199,918,567.63, representing 100% of the distributable profit[170][172]. - The 2025 semi-annual dividend plan proposes a cash dividend of RMB 0.30 per 10 shares, to be distributed on January 9, 2026[170]. - The company has committed to distributing at least 10% of the annual distributable profit in cash, or a cumulative distribution of no less than 30% of the average annual distributable profit over the last three years[191]. - The company's distributable profit for the reporting period was RMB 2,696,382,965.42[172]. Research and Development - The company has successfully developed and launched 8 vaccine products, including the 13-valent pneumococcal conjugate vaccine and the bivalent HPV vaccine[31]. - The company is focused on building mRNA vaccine technology platforms and recombinant adenovirus vaccine technology platforms in addition to its existing platforms[31]. - The company is advancing multiple innovative vaccines, including the 20-valent pneumococcal polysaccharide conjugate vaccine and mRNA vaccines for respiratory syncytial virus and varicella-zoster virus, with clinical trial approvals received[35]. - The company is conducting clinical research on multiple vaccines, including a 20-valent pneumococcal polysaccharide conjugate vaccine, which is expected to enhance its core competitiveness[87]. - The company has established leading technology platforms for bacterial vaccines and recombinant protein vaccines, and is developing mRNA and recombinant adenovirus vaccine platforms[46]. - The company emphasizes a balanced approach to R&D, considering market potential, technical maturity, and team capabilities[46]. - The company is focusing on the development of synthetic biology technologies to support future biomanufacturing industries[65]. Market Expansion and Internationalization - The company exported its vaccine products to 26 countries and regions, maintaining a leading position in China's vaccine export market (excluding COVID-19 vaccines)[30]. - The company's overseas business revenue exceeded 522 million yuan in 2025, with overseas product sales revenue of 517 million yuan, a year-on-year increase of 37%[38]. - The company successfully entered the Latin American market and achieved significant breakthroughs in global regional layout during the reporting period[39]. - The company aims to strengthen its market presence by increasing coverage and penetration rates of its vaccines across 31 provinces and municipalities in China[34]. - The company is committed to breaking the long-standing monopoly of international giants in the vaccine industry, particularly in the context of the Belt and Road Initiative[62]. - The company aims to accelerate the import substitution of innovative vaccines and expand its international presence, particularly in countries along the Belt and Road Initiative, contributing to global public health, especially in low- and middle-income countries[111]. Governance and Compliance - The company’s board of directors has confirmed the accuracy and completeness of the annual report, ensuring accountability for any misleading statements or omissions[4]. - The company has established a governance structure that complies with legal requirements, ensuring effective decision-making and risk management[123]. - The company has eliminated the supervisory board, with the audit committee now exercising the supervisory functions as of December 19, 2025[126]. - The company emphasizes investor relations management, holding multiple communication events to enhance investor understanding of its strategies and operations[128]. - The company has committed to transparent information disclosure, ensuring timely and accurate communication with investors[129]. - The company has established a comprehensive internal control mechanism to protect intellectual property rights during the research and development process[176]. - The company maintains a robust internal control system to ensure compliance with laws and regulations, enhancing operational efficiency and risk management[175][177]. Operational Efficiency and Risk Management - The company has implemented a dynamic production plan to improve operational efficiency in response to market demand and policy changes[34]. - The company is enhancing its internal control and risk management systems, revising multiple governance documents to strengthen compliance and operational efficiency[44]. - The company is addressing increasing market competition by accelerating new product development and enhancing product quality to maintain market share[115]. - The company is adapting to stricter regulatory requirements in the pharmaceutical industry to mitigate operational risks associated with policy changes[115]. - The company is implementing measures to control accounts receivable risks, as payment cycles from public health centers can be lengthy, potentially impacting cash flow[115]. Social Responsibility and Community Engagement - The company actively engages in social responsibility initiatives, including donations to health education projects and support for maternal and child health programs[186]. - The company has established a comprehensive environmental management system to minimize operational impacts on the environment and promote sustainable development[184]. - The company has actively participated in community development by donating trees to support local ecological initiatives[184]. - The company has a clear commitment to enhancing women's health through initiatives aimed at increasing HPV vaccination rates[186]. Human Resources and Talent Development - The total number of employees at the end of the reporting period is 1,981, with 170 in the parent company and 1,811 in major subsidiaries[160]. - The company has implemented a comprehensive compensation system based on the "3P" theory, which considers position, person, and performance, ensuring external market competitiveness and internal fairness[162]. - The company has established a "Sengsheng Buxi" talent training system, which includes new employee training and leadership development programs, enhancing training specificity[165]. - A talent inventory project was completed, identifying high-potential talents and optimizing the leadership capability model, forming a "412 model" for evaluating leadership competencies[166]. Management and Leadership Changes - The company is undergoing internal organizational adjustments to enhance strategic transformation and long-term growth, focusing on building a "professional, youthful, international, and Watsonized" workforce[136]. - The company has appointed new executives, including Mr. Li Wei as vice president and Mr. Li Yunchun as acting board secretary on June 16, 2025[137]. - The current board consists of 11 members, including 4 independent directors, with a focus on expertise in the vaccine industry[138]. - The management team consists of industry experts with strong capabilities in market insight, resource integration, and risk control, enhancing the company's strategic execution[65].

上海开开实业股份有限公司2025 年年度报告 公司代码：600272 公司简称：开开实业 900943 开开 B 股 上海开开实业股份有限公司 2025 年年度报告 1 / 183 上海开开实业股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 上会会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人庄虔贇、主管会计工作负责人刘光靓及会计机构负责人（会计主管人员）陈珩 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司第十一届董事会第二次会议审议通过公司2025年度利润分配预案：公司拟以实施权益分 派股权登记日登记的总股本为基数分配利润，向全体股东每10股派发现金红利人民币0.15元（含 税），B股折算成美元发放，共计分配股利3,939,779.18元，占2025年度合并归属于上市公司股东 净利润的比例为30.45%。本年度不进行送红 ...

Financial Projections - The estimated net profit for Q1 2026 is projected to be between 9,033.86 million and 9,937.25 million CNY, representing a year-on-year growth of 100.00% to 120.00%[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 8,898.58 million and 9,707.54 million CNY, indicating a growth of 120.00% to 140.00% compared to the same period last year[6] - The basic earnings per share is projected to be between 0.26 and 0.28 CNY, up from 0.13 CNY in the previous year[6] Market Expansion - The company has increased efforts in domestic and international market expansion, leading to significant growth in sales of high-value products like plant-based hollow capsules[8] Cost Management - Improved capacity utilization has effectively reduced fixed asset depreciation and other amortization expenses, contributing to the substantial increase in net profit[8] Cautionary Notes - Investors are advised to exercise caution and consider investment risks as the financial data will be finalized in the official Q1 2026 report[3][9] - The performance forecast is based on preliminary calculations by the finance department and has not yet been audited by the accounting firm[7] - The performance forecast period is from January 1, 2026, to March 31, 2026[4]

Financial Performance - Total revenue for 2025 was CNY 191,534.85 million, a decrease of 2.10% compared to the previous year[5] - Operating profit for 2025 was CNY 19,552.36 million, down 24.04% year-over-year[5] - Total profit for 2025 was CNY 18,352.59 million, reflecting a decline of 29.59% from the prior year[5] - Net profit attributable to shareholders was CNY 15,041.59 million, a decrease of 32.13% compared to the previous year[5] - The basic earnings per share for 2025 was CNY 0.44, down 32.31% from CNY 0.65 in the previous year[5] Assets and Equity - Total assets as of December 31, 2025, were CNY 405,598.53 million, a decrease of 2.17% from the beginning of the period[8] - Shareholders' equity attributable to the company was CNY 219,628.39 million, down 0.61% from the beginning of the period[8] Reasons for Decline - The decline in net profit was primarily due to reduced revenue, lower gross margins, and decreased investment income[9] Earnings Guidance - The company did not provide prior earnings guidance for 2025 before this announcement[10] Financial Data Status - The financial data presented is preliminary and subject to change upon final audit[3]

江苏太平洋石英股份有限公司2025 年年度报告 公司代码：603688 公司简称：石英股份 江苏太平洋石英股份有限公司 2025 年年度报告 二〇二六年三月二十八日 1 / 209 江苏太平洋石英股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 中汇会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人陈士斌、主管会计工作负责人张丽雯及会计机构负责人（会计主管人员）张富雷 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司第六届董事会第三次会议决议，公司2025年年度拟以实施权益分派股权登记日登记的 总股本（扣除股份回购专户内股票数量）为基数，向全体股东每10股派发现金红利0.86元（含税 ），不转增股本，不送红股，剩余未分配利润结转以后年度分配。以上利润分配预案需提交公司 2025年年度股东会审议。 截至报告期末，母公司存在未弥补 ...